MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 593200 | Name: SRI-31277

Description:

WARNING: This product is for research use only, not for human or veterinary use.

SRI-31277 is a TSP1-TGFβ inhibitor.

Chemical Structure

SRI-31277
CAS#1637468-93-9

Theoretical Analysis

MedKoo Cat#: 593200

Name: SRI-31277

CAS#: 1637468-93-9

Chemical Formula: C17H33N5O5

Exact Mass: 387.2482

Molecular Weight: 387.48

Elemental Analysis: C, 52.70; H, 8.58; N, 18.07; O, 20.64

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
SRI31277; SRI-31277; SRI 31277
IUPAC/Chemical Name
(S)-2-((S)-2-acetamido-3-hydroxypropanamido)-6-amino-N-((S)-1-amino-4-methyl-1-oxopentan-2-yl)hexanamide
InChi Key
JRTSFGRYHSHGEP-IHRRRGAJSA-N
InChi Code
InChI=1S/C17H33N5O5/c1-10(2)8-13(15(19)25)22-16(26)12(6-4-5-7-18)21-17(27)14(9-23)20-11(3)24/h10,12-14,23H,4-9,18H2,1-3H3,(H2,19,25)(H,20,24)(H,21,27)(H,22,26)/t12-,13-,14-/m0/s1
SMILES Code
CC(N[C@H](C(N[C@H](C(N[C@H](C(N)=O)CC(C)C)=O)CCCCN)=O)CO)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
TGF-​β has been a target of interest for the treatment of fibrotic diseases and certain cancers. Approaches to target TGF-​β include antagonists of the active ligand or TGF-​β receptor kinase activity. These approaches have failed in clin. trials due to a lack of effectiveness and a limited therapeutic window. In this context, newer and more selective approaches to target TGF-​β are needed.

Preparing Stock Solutions

The following data is based on the product molecular weight 387.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Lu A, Pallero MA, Lei W, Hong H, Yang Y, Suto MJ, Murphy-Ullrich JE. Inhibition of Transforming Growth Factor-β Activation Diminishes Tumor Progression and Osteolytic Bone Disease in Mouse Models of Multiple Myeloma. Am J Pathol. 2016 Mar;186(3):678-90. doi: 10.1016/j.ajpath.2015.11.003. Epub 2016 Jan 20. PubMed PMID: 26801735; PubMed Central PMCID: PMC4816696.